Diabetes Drug Labels Should Reflect Heart Failure Risk, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee endorses CV ischemic safety of AstraZeneca’s saxagliptin and Takeda’s alogliptin but recommends safety-related revisions to the labels of both DPP-4 inhibitors.